Loading clinical trials...
Loading clinical trials...
A Study of Lenvatinib in Korean Unresectable Hepatocellular Carcinoma (uHCC) Patients as a Post-marketing Surveillance
The purpose of this study is to describe the following safety and the efficacy of Lenvima for the first-line treatment indication of participants with uHHC in the post marketing setting: (1) Serious adverse events and serious adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in the precautions for use (3) Known adverse drug reactions (4) Non-serious adverse drug reactions (5) Other safety and efficacy related information.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Site #32
Cheonan, Chungcheongnam-do, South Korea
Site #35
Bucheon-si, Gyeonggi-do, South Korea
Site #38
Bucheon-si, Gyeonggi-do, South Korea
Site #06
Goyang-si, Gyeonggi-do, South Korea
Site #03
Seongnam-si, Gyeonggi-do, South Korea
Site #13
Suwon, Gyeonggi-do, South Korea
Site #27
Suwon, Gyeonggi-do, South Korea
Site #15
Uijeongbu-si, Gyeonggi-do, South Korea
Site #37
Changwon, Gyeongsangnam-do, South Korea
Site #28
Yangsan, Gyeongsangnam-do, South Korea
Start Date
May 28, 2019
Primary Completion Date
January 31, 2022
Completion Date
January 31, 2022
Last Updated
January 9, 2023
658
ACTUAL participants
Non-interventional
OTHER
Lead Sponsor
Eisai Korea Inc.
NCT07225114
NCT06454578
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05870969